Response to comment on “Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer”

Maarten J. van der Doelen; Peter H.J. Slootbeek; Niven Mehra

doi:10.1016/j.ejca.2020.11.041

Author’s reply| Volume 144, P395-396, February 2021

Download started.

Ok

Response to comment on “Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer”

Maarten J. van der Doelen
Maarten J. van der Doelen
Affiliations
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands
Search for articles by this author
Peter H.J. Slootbeek
Peter H.J. Slootbeek
Affiliations
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
Search for articles by this author
Niven Mehra
Niven Mehra
Correspondence
Corresponding author: Department of Medical Oncology, Radboud University Medical Center, PO Box 9101, Nijmegen 6500 HB, the Netherlands. Fax: +31 24 361 5025.
Contact
Affiliations
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
Search for articles by this author

Published:December 25, 2020DOI:https://doi.org/10.1016/j.ejca.2020.11.041

We thank colleagues De Vincentis and Frantellizzi [

[1]

De Vincentis G.
Frantellizzi V.

Comment on: ‘Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer’ by De Vincentis et al..

] for their thoughtful considerations on our recently published manuscript in this journal and their ongoing work on optimising patient selection for radium-223 therapy [

[1]

De Vincentis G.
Frantellizzi V.

Comment on: ‘Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer’ by De Vincentis et al..

,

[2]

van der Doelen M.J.
Isaacsson Velho P.
Slootbeek P.H.J.
Pamidimarri Naga S.
Bormann M.
van Helvert S.
et al.

Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.

].

To read this article in full you will need to make a payment

Purchase one-time access:

One-time access price info

For academic or personal research use, select 'Academic and Personal'
For corporate R&D use, select 'Corporate R&D Professionals'

Subscribe:

Already a print subscriber? Claim online access

Already an online subscriber? Sign in

Register: Create an account

Institutional Access: Sign in to ScienceDirect

References

- De Vincentis G.
- Frantellizzi V.
Comment on: ‘Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer’ by De Vincentis et al..
Eur J Cancer. 2020; ([in press])https://doi.org/10.1016/j.ejca.2020.09.041
View in Article
- van der Doelen M.J.
- Isaacsson Velho P.
- Slootbeek P.H.J.
- Pamidimarri Naga S.
- Bormann M.
- van Helvert S.
- et al.
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
Eur J Cancer. 2020; 136: 16-24
View in Article
- de Bono J.
- Mateo J.
- Fizazi K.
- Saad F.
- Shore N.
- Sandhu S.
- et al.
Olaparib for metastatic castration-resistant prostate cancer.
N Engl J Med. 2020; 382: 2091-2102
View in Article
- Slootbeek P.H.J.
- Duizer M.L.
- van der Doelen M.J.
- Kloots I.S.H.
- Kuppen M.C.P.
- Westgeest H.M.
- et al.
Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
Int J Cancer. 2021; 148: 385-395
View in Article
- Mateo J.
- Cheng H.H.
- Beltran H.
- Dolling D.
- Xu W.
- Pritchard C.C.
- et al.
Clinical outcome of prostate cancer patients with germline DNA repair mutations: retrospective analysis from an international study.
Eur Urol. 2018; 73: 687-693
View in Article
- Lozano Mejorada R.
- Castro Marcos E.
- Aragon I.M.
- Thorne H.
- Lopez Campos F.
- Sanz A.
- et al.
612MO Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: results from PROREPAIR-A study.
Ann Oncol. 2020; 31: S509-S510
View in Article
- Castro E.
- Mejorada R.L.
- Saez M.
- De Giorgi U.F.F.
- Aragón I.
- Laorden N.R.
- et al.
876P - Impact of germline mutations in homologous recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)..
Ann Oncol. 2019; 30: v343-v344
View in Article
- Van der Doelen M.J.
- Mehra N.
- Hermsen R.
- Janssen M.J.R.
- Gerritsen W.R.
- Van Oort I.M.
Patient selection for radium-223 therapy in patients with bone metastatic castration-resistant prostate cancer: new recommendations and future perspectives.
Clin Genitourin Cancer. 2019; 17: 79-87
View in Article
- Frantellizzi V.
- Farcomeni A.
- Follacchio G.A.
- Pacilio M.
- Pellegrini R.
- Pani R.
- et al.
A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with (223)Radium-dichloride.
Ann Nucl Med. 2018; 32: 142-148
View in Article
- van Dessel L.F.
- van Riet J.
- Smits M.
- Zhu Y.
- Hamberg P.
- van der Heijden M.S.
- et al.
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
Nat Commun. 2019; 10: 5251
View in Article

Article info

Publication history

Published online: December 25, 2020

Accepted: November 25, 2020

Received in revised form: November 12, 2020

Received: October 30, 2020

Identification

DOI: https://doi.org/10.1016/j.ejca.2020.11.041

Copyright

ScienceDirect

Access this article on ScienceDirect

Linked Article

Comment on: ‘Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer’ by De Vincentis et al
European Journal of CancerVol. 144
- Preview
  We were very impressed by the interesting and intriguing work of van der Doelen et al. [1] recently published in your Journal . This inspires some considerations that we would gladly share with the scientific community.
- Full-Text
- PDF
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer
European Journal of CancerVol. 136
- Preview
  Radium-223 is a targeted alpha radiation therapy for metastatic castration-resistant prostate cancer. DNA damage repair (DDR) defective prostate cancers, specifically genetic aberrations leading to homologous recombination deficiency (HRD), accumulate irreparable DNA damage following genotoxic treatment. This retrospective study assessed DDR mutation status in patients treated with radium-223, investigating their association with efficacy and overall survival (OS).
- Full-Text
- PDF
Open Access

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Response to comment on “Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer”

Purchase one-time access:

Subscribe:

References

Article info

Publication history

Identification

Copyright

ScienceDirect

Linked Article

Related Articles